dw-anzcxqaqavhl

FDA refuses to review Nabriva’s injectable antibiotic for urinary tract infections

pharmafile | May 1, 2019 | News story | Research and Development, Sales and Marketing |  Contepo, Nabriva, pharma, urinary tract infections 

Biopharma firm Nabriva Therapeutics has revealed that its antibiotic Contepo (fosfomycin) has been rejected for review by the FDA as an injectable treatment for complicated urinary tract infections (cUTI), including acute pyelonephritis.

According to the manufacturer, Contepo is the first intravenously administered epoxide therapy in the US.

The company received a complete response letter (CRL) from the US regulator, outlining issues relating to one of Nabriva’s contract manufacturing facilities, identified during a recent inspection. No additional clinical data was requested, and the safety of the drug was not brought into question.

Nabriva has said that it intends to request a ‘Type A’ meeting with the FDA to discuss the raised issues.

Advertisement

“We will be working with the FDA in the coming weeks to gain a full understanding of the FDA’s comments, with the goal of bringing this important treatment to patients as quickly as possible,” said Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics.

Antibiotic resistance is leading to around two million serious infections per year in the US alone, while almost 23,000 deaths as a result.

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

The Gateway to Local Adoption Series

Latest content